welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
CureDuchenne Invests in ZappRx Platform to Streamline Specialty Prescribing for Patients Suffering from Duchenne Muscular Dystrophy
ZappRx, Inc., a digital health company that streamlines specialty medication prescribing, announced today that CureDuchenne, a global leader in research, patient care, and innovation in improving and extending the lives of those living with Duchenne muscular dystrophy (DMD), has invested in the ZappRx platform, in order to add Duchenne to the ZappRx platform in 2019.
Duchenne muscular dystrophy is the most common and severe form of muscular dystrophy that primarily affects boys. The genetic disease causes a progressive loss of muscle strength subsequent to a loss of a protein called dystrophin, which normally protects muscle fibers from breaking down. Approximately 15,000 US patients are affected with Duchenne, with a total of 300,000 patients worldwide. While there is currently no cure, there are a growing number of specialty pharmaceuticals emerging from clinical trials which may help significantly with disease management. ZappRx and CureDuchenne’s partnership will drive a more streamlined delivery of these life-changing drugs to Duchenne patients.

rareRelated
-
Strength Training in Duchenne Muscular DystrophyDuchenne muscular dystrophy (DMD) is a d...
-
Solid Biosciences Reports First Quarter 2019 Financial Results and Provides Business UpdateSolid Biosciences Inc. (Nasdaq: SLDB) to...
-
Therapeutic Potential of Stem Cell in the Treatment of Duchenne Muscular DystrophyHere, we will describe the therapeutic p...
-
Systemic Gene Delivery Clinical Trial for Duchenne Muscular DystrophyThe proposed clinical trial is a single-...
-
Study of DS-5141b in Patients With Duchenne Muscular DystrophyThis is a phase I/II study to evaluate t...
-
Clinical trial of gene therapy for Duchenne muscular dystrophy underway at University of Florida HealthScreening has resumed in a clinical tria...
-
Long-Term Outcomes of Ataluren in Duchenne Muscular DystrophyThis study is a long-term study of atalu...
-
ICER Document Reviews Effectiveness of 3 Duchenne MD TherapiesThe Institute for Clinical and Economic ...
-
Wave Life Sciences Receives US Orphan Drug and Rare Pediatric Disease Designations for WVE-210201Wave Life Sciences Ltd., a biotechnology...